Drug Sponsors

NanoViricides raises $5M in shelf offering

Monday, July 2, 2012 11:09 AM

NanoViricides, a West Haven, Conn.-based development stage company that creates special purpose nanomaterials for antiviral therapy, has raised $5 million drawing down on its previously announced universal registered shelf “Form S-3” offering. The registered shelf offering became effective on April 29, 2010, and continues to remain effective.

More... »

BMS acquires Amylin Pharmaceuticals, expands diabetes alliance with AZ

Monday, July 2, 2012 09:59 AM

Global biopharmaceutical company Bristol-Myers Squibb (BMS) has agreed to acquire Amylin Pharmaceuticals of San Diego for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or an aggregate purchase price of approximately $5.3 billion.

More... »

Biogen Idec, Isis partner on antisense program targeting myotonic dystrophy

Friday, June 29, 2012 03:12 PM

Weston, Mass.-based Biogen Idec and Isis Pharmaceuticals of Carlsbad, Calif., have entered into an exclusive, worldwide option and collaboration agreement to develop and commercialize a novel antisense drug for the treatment of myotonic dystrophy type 1 (DM1), also known as Steinert disease.

More... »

GSK further extends HGS tender offer

Friday, June 29, 2012 02:14 PM

GlaxoSmithKline has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash to 5:00 p.m. EST on July 20, 2012.

More... »

BioInvent reorganizes after TB-402 bust

Friday, June 29, 2012 12:53 PM

BioInvent International, a Swedish research-based pharmaceutical company that focuses on developing antibody drugs, has decided to initiate negotiations with trade unions regarding organizational changes due to halting development of the antithrombotic agent TB‑402.

More... »

AMAG realigns operating cost structure, closes Cambridge plant

Thursday, June 28, 2012 03:34 PM

AMAG Pharmaceuticals of Lexington, Mass., has announced a number of changes to its operating expenses that further align its cost structure with the company's focus on advancing Feraheme and expanding its product portfolio with commercial stage assets.

More... »

Janssen acquires CorImmun

Thursday, June 28, 2012 11:09 AM

Janssen-Cilag GmbH has completed the acquisition of CorImmun GmbH, a privately held drug development company in Germany, for an undisclosed upfront payment and a contingent future clinical milestone payment.

More... »

Roche to streamline R&D activities, close New Jersey site

Wednesday, June 27, 2012 10:46 AM

Roche has decided to consolidate activities within its research and early development division, resulting in the closure of the company’s Nutley, N.J., site. Research and development activities will be consolidated at the existing sites in Germany and Switzerland, focusing on oncology, virology, metabolism and neuroscience.

More... »

Quintiles to offer jobs to 100 Merck Serono employees affected by cuts

Wednesday, June 27, 2012 10:16 AM

CRO Quintiles has committed to make at least 100 employment offers within the next three months to Merck Serono employees primarily working in global development and medical function in Geneva.

More... »

Amgen, actress Maura Tierney launch ‘Chemotherapy: Myths or Facts’ campaign

Monday, June 25, 2012 03:30 PM

Amgen, a biotech based in Thousand Oaks, Calif., has launched Chemotherapy: Myths or Facts, an awareness campaign for cancer patients and their caregivers featuring Emmy-nominated actress and breast cancer survivor Maura Tierney.

More... »